Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TARGINIQ vs ANEXSIA 7.5/325
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
TARGINIQ combines naloxegol, a peripherally acting mu-opioid receptor antagonist (PAMORA), with oxycodone, a full mu-opioid receptor agonist. Naloxegol reduces opioid-induced constipation by blocking opioid effects in the gastrointestinal tract without affecting central analgesia.
Hydrocodone is a mu-opioid receptor agonist, producing analgesia and euphoria. Acetaminophen inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis and providing analgesic and antipyretic effects.
FDA-approved: Management of severe chronic pain requiring daily around-the-clock opioid treatment, in patients who have responded to and tolerated oxycodone and require treatment for opioid-induced constipation.,Off-label: Not specified
Management of moderate to moderately severe pain where treatment with an opioid is appropriate and for which alternative treatments are inadequate
1 tablet orally every 12 hours, each tablet containing oxycodone hydrochloride 10 mg and naloxone hydrochloride 5 mg (as naloxone hydrochloride dihydrate). Dose may be titrated based on analgesic requirements; maximum daily dose: oxycodone 80 mg and naloxone 40 mg.
1 tablet (hydrocodone 7.5 mg / acetaminophen 325 mg) orally every 4 to 6 hours as needed for pain; maximum 6 tablets per day (hydrocodone 45 mg / acetaminophen 1950 mg).
Oxycodone terminal half-life is 3.5-4.0 hours; naloxone half-life is 1-1.5 hours. The prolonged-release formulation yields a longer apparent half-life, supporting twice-daily dosing.
Hydrocodone: 3.8-4.5 hours (immediate-release). Acetaminophen: 2-3 hours. Clinical note: Half-life prolonged in hepatic impairment; requires dose adjustment.
Oxycodone: primarily hepatic via CYP3A4 and CYP2D6. Naloxegol: primarily hepatic via CYP3A4.
Hydrocodone: CYP3A4 and CYP2D6; Acetaminophen: primarily via glucuronidation (UGT1A1, UGT1A6, UGT1A9) and sulfation, with minor oxidation by CYP2E1.
Oxycodone is primarily excreted renally as noroxycodone and free oxycodone; naloxone undergoes extensive hepatic metabolism and is excreted renally as naloxone-3-glucuronide. For TARGINIQ, approximately 87% of the dose is eliminated in urine: 19% as unchanged oxycodone, 1% as unchanged naloxone, and the remainder as metabolites. Fecal excretion accounts for ~10%.
Renal: ~90-100% as hydrocodone metabolites (conjugated) and unchanged hydrocodone; ~60% as acetaminophen metabolites (glucuronide, sulfate, cysteine); <5% unchanged acetaminophen. Biliary/fecal: <5%.
Oxycodone: 45% bound primarily to albumin. Naloxone: approximately 40% bound predominantly to albumin.
Hydrocodone: ~20-30% (albumin). Acetaminophen: ~10-25% (albumin).
Oxycodone: Vd 2.6 L/kg, indicating extensive tissue distribution. Naloxone: Vd 2.1 L/kg.
Hydrocodone: 3-4 L/kg (extensive tissue distribution). Acetaminophen: ~1 L/kg (uniformly distributed).
Oral bioavailability of oxycodone: 60-87% (first-pass metabolism). Naloxone oral bioavailability: <2% due to extensive first-pass hepatic metabolism, allowing local gastrointestinal effect without significant systemic opioid antagonism.
Oral: Hydrocodone ~70% (high first-pass metabolism); Acetaminophen ~85-90% (minimal first-pass).
For GFR <60 m L/min: initiate at 50% of usual dose and titrate cautiously. For GFR <30 m L/min: consider alternative therapy; if used, reduce starting dose by 50% and monitor closely. Not recommended in end-stage renal disease (GFR <15 m L/min).
For GFR 30-59 m L/min: administer every 6 hours; maximum 4 tablets per day. For GFR 15-29 m L/min: administer every 8 hours; maximum 3 tablets per day. For GFR <15 m L/min: not recommended due to accumulation of metabolites.
Child-Pugh Class A: no adjustment required. Child-Pugh Class B: initiate at 50% of usual dose and titrate cautiously. Child-Pugh Class C: contraindicated due to risk of naloxone accumulation and CNS effects.
Child-Pugh Class A: no adjustment necessary. Child-Pugh Class B: reduce dose by 25-50% and extend dosing interval to every 6-8 hours; maximum 4 tablets per day. Child-Pugh Class C: contraindicated due to risk of hepatotoxicity.
Not recommended for use in pediatric patients (≤18 years) due to lack of safety and efficacy data.
Not recommended for pediatric patients; safety and efficacy not established for children under 18 years. For adolescents ≥18 years: adult dosing.
Initiate at the lower end of the dosing range (e.g., 1 tablet every 12 hours) and titrate cautiously. Monitor for signs of CNS depression, constipation, and respiratory depression. Consider baseline renal and hepatic function for dose adjustments.
Initiate at 1 tablet (hydrocodone 5 mg / acetaminophen 325 mg) every 6 hours as needed; titrate cautiously due to increased sensitivity, decreased renal function, and risk of respiratory depression. Maximum 4 tablets per day.
Risk of addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion of even one dose of TARGINIQ, especially by children, can cause fatal respiratory depression; neonatal opioid withdrawal syndrome; opioid-induced hyperalgesia and allodynia; concomitant use with CYP3A4 inhibitors or discontinuation of CYP3A4 inducers may increase naloxegol exposure and risk of adverse reactions.
Addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; risks from concomitant use with benzodiazepines or other CNS depressants; hepatotoxicity due to acetaminophen.
Addiction, abuse, and misuse,Life-threatening respiratory depression,Accidental ingestion,Neonatal opioid withdrawal syndrome,Opioid-induced hyperalgesia and allodynia,CYP3A4 inhibitor/inducer interactions with naloxegol,Gastrointestinal obstruction: naloxegol is contraindicated in patients with known or suspected gastrointestinal obstruction,Risk of severe opioid withdrawal symptoms with abrupt discontinuation or naloxegol dose increase
Risk of opioid addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; risks from concomitant use of alcohol, benzodiazepines, or other CNS depressants; hepatotoxicity; severe hypotension; adrenal insufficiency; seizures; GI obstruction; impaired mental/physical abilities; use in elderly, cachectic, or debilitated patients; renal impairment; hepatic impairment; pregnancy; labor and delivery; nursing mothers; pediatric use; driving and operating machinery.
Significant respiratory depression,Acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment,Known or suspected gastrointestinal obstruction,Concurrent use of strong CYP3A4 inhibitors (e.g., clarithromycin, ketoconazole) with naloxegol,Hypersensitivity to oxycodone, naloxegol, or any component of the formulation
Significant respiratory depression; acute or severe bronchial asthma; known or suspected GI obstruction; hypersensitivity to hydrocodone or acetaminophen; concomitant use of MAOIs or within 14 days of such therapy.
Take on an empty stomach at least 1 hour before or 2 hours after a meal. Avoid grapefruit juice and other CYP3A4 inhibitors in food, as they may increase naloxegol levels.
Avoid alcohol consumption due to increased risk of acetaminophen hepatotoxicity and CNS depression. No specific food restrictions, but grapefruit juice may theoretically affect hydrocodone metabolism via CYP3A4 inhibition; however, clinical significance is uncertain.
Prolonged use of opioids during pregnancy can result in neonatal opioid withdrawal syndrome (NOWS). First trimester: Limited data; animal studies show increased risk of neural tube defects at high doses. Second and third trimesters: Chronic use may lead to fetal dependence and withdrawal at birth.
FDA Category C (hydrocodone) and Category D (acetaminophen) in third trimester. First trimester: Acetaminophen associated with rare gastroschisis; hydrocodone risk of neural tube defects. Second trimester: No major malformations except with prolonged opioid use. Third trimester: Acetaminophen safe; hydrocodone risk of neonatal opioid withdrawal syndrome (NOWS). Avoid near term.
Oxycodone and naloxone are excreted in breast milk. Oxycodone M/P ratio approximately 3.2. Use with caution; monitor infant for respiratory depression and sedation. Consider risk of infant opioid exposure.
Hydrocodone/acetaminophen excreted in breast milk. M/P ratio unknown. Hydrocodone relative infant dose <3% of weight-adjusted maternal dose. Acetaminophen relative infant dose <2%. Use with caution; monitor infant for sedation, apnea, poor feeding. Highest risk in CYP2D6 ultrarapid metabolizers.
Pregnancy may increase clearance of oxycodone; dose adjustments may be required. However, no specific guidelines. Use lowest effective dose; avoid prolonged use. Taper if discontinuing to prevent withdrawal.
Increased clearance of hydrocodone in pregnancy may require dose adjustment; monitor for inadequate analgesia. Acetaminophen pharmacokinetics unchanged. Avoid high doses (hepatotoxicity risk). Consider baseline hepatic function. No specific dose adjustment recommended; titrate to effect.
TARGINIQ (naloxegol) is a peripherally acting mu-opioid receptor antagonist (PAMORA) indicated for opioid-induced constipation (OIC) in adults with chronic non-cancer pain. It does not cross the blood-brain barrier, so it does not reverse central analgesia or precipitate opioid withdrawal. Contraindicated in patients with known or suspected gastrointestinal obstruction. Administer on an empty stomach at least 1 hour before or 2 hours after a meal. Avoid use with strong CYP3A4 inhibitors (e.g., clarithromycin, ketoconazole) as they increase naloxegol exposure. Dose adjustments needed for moderate or severe hepatic impairment.
ANEXSIA 7.5/325 (hydrocodone/acetaminophen) carries a boxed warning for acetaminophen hepatotoxicity; maximum acetaminophen dose from all sources should not exceed 4 g/day. Hydrocodone is metabolized by CYP2D6 to hydromorphone; ultrarapid metabolizers may experience toxicity. Avoid concurrent use with other CNS depressants including alcohol. Prescribe with caution in patients with renal impairment (hydrocodone accumulation) or hepatic impairment (acetaminophen toxicity). Monitor for signs of respiratory depression, especially at therapy initiation and dose titration. Use the lowest effective dose for the shortest duration.
Take TARGINIQ on an empty stomach, at least 1 hour before or 2 hours after eating.,Do not crush or chew the tablet; swallow it whole with water.,If you miss a dose, skip it and take the next dose at the regular time. Do not take two doses at once.,Common side effects include abdominal pain, diarrhea, nausea, gas, and headache. Call your doctor if you have severe or persistent symptoms.,Seek immediate medical attention if you have severe stomach pain, vomiting, or if you are unable to pass stool (possible bowel obstruction).,Inform your doctor about all medications you take, especially strong CYP3A4 inhibitors like certain antibiotics or antifungals.,TARGINIQ does not affect the pain relief from your opioid medication; continue taking your pain medicine as prescribed.,Store at room temperature away from moisture and heat.
Do not exceed 6 tablets per day due to acetaminophen content.,Avoid alcohol while taking this medication.,Do not drive or operate heavy machinery until you know how this medication affects you.,Take exactly as prescribed; do not share with others.,Seek emergency help if you experience difficulty breathing, severe drowsiness, or signs of allergic reaction.,Store securely out of reach of children and dispose of unused medication properly.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TARGINIQ vs ANEXSIA 7.5/325, answered by our medical review team.
TARGINIQ is a Opioid Analgesic Combination that works by TARGINIQ combines naloxegol, a peripherally acting mu-opioid receptor antagonist (PAMORA), with oxycodone, a full mu-opioid receptor agonist. Naloxegol reduces opioid-induced constipation by blocking opioid effects in the gastrointestinal tract without affecting central analgesia.. ANEXSIA 7.5/325 is a Opioid Analgesic Combination that works by Hydrocodone is a mu-opioid receptor agonist, producing analgesia and euphoria. Acetaminophen inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis and providing analgesic and antipyretic effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TARGINIQ and ANEXSIA 7.5/325 depend on the specific clinical indication. These are both Opioid Analgesic Combination agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TARGINIQ is: 1 tablet orally every 12 hours, each tablet containing oxycodone hydrochloride 10 mg and naloxone hydrochloride 5 mg (as naloxone hydrochloride dihydrate). Dose may be titrated based on analgesic requirements; maximum daily dose: oxycodone 80 mg and naloxone 40 mg.. The standard adult dose of ANEXSIA 7.5/325 is: 1 tablet (hydrocodone 7.5 mg / acetaminophen 325 mg) orally every 4 to 6 hours as needed for pain; maximum 6 tablets per day (hydrocodone 45 mg / acetaminophen 1950 mg).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TARGINIQ and ANEXSIA 7.5/325 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TARGINIQ is classified as Category C. Prolonged use of opioids during pregnancy can result in neonatal opioid withdrawal syndrome (NOWS). First trimester: Limited data; animal studies show increased risk of neural tube. ANEXSIA 7.5/325 is classified as Category C. FDA Category C (hydrocodone) and Category D (acetaminophen) in third trimester. First trimester: Acetaminophen associated with rare gastroschisis; hydrocodone risk of neural tube d. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.